Multiple members of the let-7 family of miRNAs are often repressed in human cancers 1,2 , thereby promoting oncogenesis by derepressing targets such as HMGA2, K-Ras and c-Myc 3,4 . However, the mechanism by which let-7 miRNAs are coordinately repressed is unclear. The RNA-binding proteins LIN28 and LIN28B block let-7 precursors from being processed to mature miRNAs 5-8 , suggesting that their overexpression might promote malignancy through repression of let-7. Here we show that LIN28 and LIN28B are overexpressed in primary human tumors and human cancer cell lines (overall frequency B15%), and that overexpression is linked to repression of let-7 family miRNAs and derepression of let-7 targets. LIN28 and LIN28b facilitate cellular transformation in vitro, and overexpression is associated with advanced disease across multiple tumor types. Our work provides a mechanism for the coordinate repression of let-7 miRNAs observed in a subset of human cancers, and associates activation of LIN28 and LIN28B with poor clinical prognosis.
Human tumors show a global reduction in miRNA expression 1, 2 . Inhibition of the miRNA pathway through knockdown of miRNA processing enzymes promotes cellular transformation and tumorigenesis; this effect can be attenuated by ectopic expression of let-7g, suggesting that inhibition of let-7 processing is central to promoting the transformed state 3 . Low levels of let-7 correlate with increased transformation capacity in vitro 3 , and have been observed in various malignancies, including lung cancer 9,10 , hepatocellular carcinoma 11 , melanoma 12 and ovarian cancer 13 . Overexpression of let-7 represses cellular proliferation pathways, inhibits cell growth and impairs tumor development in both xenograft models and in an autochthonous model of non-small-cell lung cancer 3, [14] [15] [16] . Copy number loss 3, [17] [18] [19] and epigenetic silencing 20 of individual let-7 family members have been reported in human cancers, and such events have been suggested to contribute to the disease state. However, in tissues where let-7 family members are coexpressed, inactivation of individual let-7 miRNAs would be expected to only modestly decrease let-7 dosage, given the functional redundancy among family members. Therefore, we hypothesized that activation of LIN28 and LIN28B could serve as a physiological mechanism by which levels of all miRNAs in the let-7 family are coordinately repressed in the context of human malignancy.
We initially sought to determine whether overexpression of murine Lin28 could promote cellular transformation in experimental settings. We observed that overexpression of Lin28 in NIH/3T3 cells potently depletes levels of multiple mature miRNAs in the let-7 family ( Fig. 1a ), leading to a concomitant increase in protein abundance of c-Myc, a let-7 target (Fig. 1b) . NIH/3T3 cells overexpressing Lin28 formed colonies in soft agar ( Fig. 1c,d ) at a frequency comparable to BCR-ABL ( Supplementary Fig. 1 online) and slightly lower than that reported for c-Myc (1-2%), both of which are weakly transforming in this assay 21 . Expression of Lin28 together with BCR-ABL1 resulted in an increase in both colony size and number as compared with either Lin28 or BCR-ABL1 alone ( Supplementary Fig. 1 ). NIH/3T3 cells expressing either Lin28 or human LIN28B formed tumors in nude mice ( Supplementary Fig. 1b and Supplementary Table 1 online). Although the tumors were small and of delayed latency, they showed evidence of local invasion ( Supplementary Fig. 1b ), similar to what has been observed upon global inhibition of miRNA processing 3 , and consistent with a recent report that Lin28 enhances metastasis 22 . Coexpression of Lin28 and 7S21L (a let-7 loop mutant capable of being processed to mature let-7 in the presence of Lin28) 23 abrogated the ability to form colonies in semisolid medium ( Fig. 1c,d) ; thus, Lin28 transforms NIH/3T3 cells through the derepression of let-7 target genes. We also observed that Lin28 overexpression enhanced transformation of a mouse lung adenocarcinoma cell line in which impairment of miRNA processing had been previously reported to be transforming 3 ( Supplementary Fig. 2 online).
We next tested Lin28 for its ability to transform cytokine-dependent BaF/3 cells to factor independence. Overexpression of Lin28 in BaF/3 cells potently depleted mature let-7 family members and led to the upregulation of the let-7 targets K-Ras and c-Myc ( Fig. 1e,f ). Coexpression of Lin28 and a weakly transforming variant of c-Src (Src/ Y530F) 52 conferred factor independence upon Ba/F3 cells ( Fig. 1g,h ) and strongly promoted growth in semisolid medium ( Fig. 1i ). Mice injected with Ba/F3 cells coexpressing Lin28 and Src/Y530F succumbed to leukemic disease more rapidly than mice injected with Ba/F3 cells expressing Src/Y530F alone ( Fig. 1j ). Lin28 cooperated similarly with a weakly transforming variant of c-Abl 52 (Abl/G2A) to transform Ba/F3 cells ( Fig. 1k-m) . Notably, BCR-ABL, v-Abl and v-Src have all been suggested to transform lymphoid cells through a similar pathway 24 . Together, these experiments show that overexpression of Lin28 facilitates cellular transformation in multiple in vitro assays and accelerates disease progression in a mouse model.
To determine whether LIN28 and LIN28B are aberrantly expressed in the setting of human cancer, we examined LIN28 expression by microarray analysis of a large panel of human cancer cell lines; we observed expression in 3.2% of cell lines (17/527; Supplementary  Fig. 3a online), including lines derived from germ cell tumors, Wilms' tumor and hepatocellular carcinomas (HCC). Analysis of microarray data available for the National Cancer Institute panel of 60 cell lines (NCI-60) revealed LIN28 expression in 5% (3/60) and LIN28B expression in 10% (6/60) of the lines ( Supplementary Fig. 3b and Supplementary Table 2 online). We also conducted quantitative PCR analysis on a select panel of cancer cell lines and found several that express LIN28B, including multiple cell lines derived from individuals in the blast crisis phase of chronic myeloid leukemia (CML) (Supplementary Table 2 ). Examination of LIN28 expression in a range of primary tumor types by immunohistochemistry on a multitumor tissue microarray showed that LIN28 was highly overexpressed in diverse tumor types including colon cancer, breast cancer, lung cancer and cervical cancer ( Supplementary Fig. 4 and Supplementary  Table 3 online). Together, these data show that LIN28 and LIN28B are aberrantly expressed in B15% of surveyed cancer samples.
We surmised that activation of LIN28 and LIN28B could represent a physiological means by which let-7 levels are coordinately repressed in a subset of human cancers, and that overexpression of these factors might modify disease severity. Given that we observed overexpression in cell lines from individuals with CML, we examined expression of LIN28 and LIN28B in peripheral blood from individuals in either chronic phase (CP) or blast crisis (BC) of CML. LIN28 expression was detected more frequently in individuals with BC-CML (42.8%, 6/14) or accelerated phase CML (40%, 4/10) than in individuals with CP-CML (9.1%, 1/11) ( Fig. 2a ). Furthermore, analysis of 13 paired CP-BC samples showed activation of LIN28B upon progression to BC in three individuals (23%, 3/13) (Supplementary Table 4 online). Therefore, LIN28 and LIN28B expression is associated with disease progression in a subset of CML cases. Notably, we observed that expression of HMGA2, a let-7 target, shows a similar relationship with disease progression in CML, as has also been reported elsewhere 25 ( Supplementary Fig. 5 online) . This supports the notion that LIN28 and LIN28B activation drives progression in CML through let-7 pathways. To determine whether cell lines derived from individuals with BC-CML might be dependent on LIN28 and LIN28B for growth, we inhibited LIN28B expression in K562 cells by RNA interference. Infection of K562 cells with a short hairpin RNA (shRNA) against LIN28B restored levels of mature let-7 miRNAs (Fig. 2b,c) , decreased abundance of c-MYC and K-Ras ( Fig. 2d) , impaired proliferative capacity and the ability to form colonies in soft agar ( Fig. 2e ,f) and resulted in morphological changes suggestive of differentiation ( Fig. 2g) 26 . Similar results were obtained in a second CML-BC cell line and in a lung adenocarcinoma cell line (Supplementary Figs. 6 and 7 online), both of which express LIN28B.
We next sought to determine whether LIN28 and LIN28B might be similarly associated with advanced disease in HCC. We conducted genome-wide mRNA and microRNA profiling on 89 HCC samples. LIN28B was highly expressed in a subset of HCCs, and these tumors showed coordinate repression of all let-7 family miRNAs ( Fig. 3a) . Gene set enrichment analysis revealed that expression of let-7 target genes and myc target genes was significantly enriched in LIN28Bexpressing tumors (Fig. 3b ), suggesting that LIN28B represses let-7 and functionally activates let-7 targets in the setting of HCC. Tumors with high LIN28B expression accumulated in a molecular subclass defined by a meta-analysis of published transcriptome datasets (Y.H. and T.R.G., data not shown), which is characterized by high serum alpha-fetoprotein concentration, higher tumor grade and c-MYC activation (P ¼ 0.006, Fisher's exact test). Consistently, LIN28B expression was observed in 66% (4/6) of tumors from individuals with serum alpha-fetoprotein (AFP) 4 10,000 ng/ml as compared to 16.3% (15/92) (P ¼ 0.00981, Fisher's exact test) of individuals with AFP o 10,000 ng/ml. LIN28B-expressing tumors also fell predominantly within a subclass characterized by a proliferative nature as defined by unsupervised clustering 27 (P ¼ 0.004), and most LIN28B-expressing tumors were of advanced stage. Moreover, LIN28B expression was associated with a significantly increased incidence of early recurrence (within 2 years of resection, P ¼ 0.02, log-rank test), but was not associated with late recurrence (Fig. 3c,d) . Early recurrence is an indicator of malignant disease, whereas late recurrence is thought to occur as a de novo event from the carcinogenetic microenvironment of the cirrhotic liver 28 . Knockdown of LIN28B in HepG2 cells (an HCC cell line expressing LIN28B) led to a marked decrease in the number of colonies formed in semisolid medium (Fig. 3e) . Together, these results demonstrate that LIN28B is associated with advanced disease and poor clinical outcome in HCC.
To determine whether LIN28 and LIN28B are associated with advanced malignancy in other settings, we interrogated published microarray data from multiple tumor types and found high LIN28 and/or LIN28B expression in a discrete subset of human tumors including Wilms' tumor ( Supplementary Fig. 8 online) , ovarian carcinoma ( Supplementary Fig. 9 online) and germ cell tumors (J. West et al., unpublished data). Markedly, LIN28 and LIN28B expression was specifically associated with advanced disease in all of these tumor types. In Wilms' tumor, LIN28 and LIN28B expression was observed only in stage 3 or stage 4 tumors (P ¼ 0.00361, Fisher's exact test), but not in lower-stage tumors ( Supplementary Fig. 8 ). Among ovarian carcinomas, LIN28 and LIN28B expression was observed predominantly in tumors of histological grade 2 or 3, rather than grade 1 ( Supplementary Fig. 9 ).
Various mechanisms may explain LIN28 and LIN28B expression in human cancers, including genomic amplification, aberrant hypomethylation and expression in a rare cell of origin that acquires additional malignant lesions. Amplification of regions containing the LIN28 (1p36) 29 and LIN28B (6q21) 30, 31 loci in human cancers has been reported. We surveyed SNP array data from 3,131 primary tumors and cell lines to check for focal copy number changes at the LIN28 and LIN28B loci. Although we observed no appreciable copy number changes at the LIN28 locus, a small subset of cancers showed focal copy number increases of LIN28B (1.7% overall) (Supplementary Table 5 and Supplementary Fig. 10 online) . However, most amplification events were rare and typically broad, involving both LIN28B and numerous neighboring genes. Analysis of SNP array data in 31 CML-BC samples (22 myeloid, 9 lymphoid) revealed no focal alterations at either the LIN28 or LIN28B loci (data not shown). Thus, although genomic amplification may explain LIN28B expression in a small number of tumors, it is unlikely to be a dominant mechanism of activation. We also assessed methylation status at a CpG island located within the LIN28B locus and observed relative hypomethylation in LIN28B-expressing cell lines ( Supplementary Fig. 11 online) , suggesting that aberrant hypomethylation may poise the LIN28B locus for transcriptional activation in some tumors. This region of aberrant hypomethylation overlaps with a recently defined c-Myc binding site within the LIN28B locus 32 . Together with our observation that
LIN28B-expressing tumors cluster in a high-Myc expression subclass, this suggests that
Myc may transcriptionally activate LIN28B in some contexts. Notably, there have been several reported cases of Wilms' tumor with a translocation involving 6q21 (refs. [33] [34] [35] [36] , the band on which LIN28B is located. To determine whether these translocations may be associated with altered expression of LIN28B, we analyzed an individual with sporadic Wilms' tumor with a previously described chromosomal translocation t(6;15)(q21;q21) 33, 37 . Previous mapping by FISH analysis had narrowed the 6q21 breakpoint in this case to a region intergenic to two 6q21 genes, HACE1 and LIN28B, and had demonstrated that loss of HACE1 expression in a cohort of individuals with Wilms' tumor 37 was associated with altered methylation of several CpG islands in the region, including CpG-29 directly adjacent to the LIN28B gene ( Supplementary Fig. 12a online) . To further map the 6q21 breakpoint in this case, we conducted a DNA blot assay using probes from the intergenic region. A probe covering CpG-29 and flanking sequences lying B3-4 kb upstream of the LIN28B transcriptional start site showed rearrangement using PstI-digested genomic DNA from the index Wilms' tumor case compared to matching normal kidney and other controls ( Supplementary Fig. 12a-c) . Moreover, quantitative RT-PCR showed markedly increased expression of LIN28B in the index case compared to subject-matched normal kidney ( Supplementary  Fig. 12d) . A second Wilms' tumor case carrying a t(6;15) translocation ( Supplementary Fig. 12e ) also showed notably increased expression of LIN28B in the tumor sample compared with normal kidney (Supplementary Fig. 12f ). Therefore, LIN28B may be activated by translocation, although the frequency of such events remains to be determined.
Lin28 and Lin28b are expressed in various stem cell populations 8, 38, 39 , although there is scarce expression in most terminally differentiated somatic tissues 40 . Although our data suggest that altered gene expression of LIN28 or LIN28B can promote tumorigenesis and is associated with advanced malignancy, we cannot rule out the possibility that in some settings LIN28 or LIN28B may be endogenously expressed in a rare cell of origin that develops into an aggressive tumor. We have observed relatively strong LIN28 expression within cells of the normal ovarian surface epithelium, thought to be the cells of origin of epithelial ovarian cancer ( Supplementary Fig. 9 ) 41 . Some poor-prognosis HCCs have also been suggested to arise from a primitive cell of origin that shares gene expression patterns with fetal hepatoblasts 42 .
Recently, LIN28 was used together with OCT4, NANOG and SOX2 to reprogram human somatic fibroblasts to pluripotency 43 . Overexpression of other stem cell factors such as BMI1 (ref. 44 ) and OCT4 (refs. 45, 46) has been reported to promote oncogenesis by driving self-renewal and proliferation. Moreover, poorly differentiated, aggressive human tumors have recently been shown to have an embryonic stem cell-like gene expression signature 47 ; other embryonic factors have also been reported to have roles in tumor progression 48, 49 . Our data add LIN28 and LIN28B to a growing list of embryonic genes involved in oncogenesis and suggest a mechanism whereby repression of let-7 by LIN28 and LIN28B may help to confer self-renewal capacity on cancer stem cells 50 . Antagonizing LIN28 and/or LIN28B function in tumors that overexpress these genes may provide a means to reactivate the expression of let-7 family tumor suppressors, and may thus be therapeutically beneficial.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. NCBI GEO: microarray datasets analyzed in this manuscript are deposited under the following accession codes: GSE11024, GSE6222, GSE9843, GSE9891, GSE4170.
Note: Supplementary information is available on the Nature Genetics website.
ONLINE METHODS
Cell culture. Cell lines were originally obtained from ATCC and cultured under standard conditions. BaF3/AblG2A and Baf3/SrcY530F lines have been described elsewhere 52 . LKR cells were derived from a mouse adenocarcinoma 53 and were a gift of C. Kim.
Antibodies. We used the following antibodies for immunoblotting: c-Myc (Santa Cruz, sc-764), K-Ras (Santa Cruz, sc-30), Abl-K12 (Santa Cruz, sc-131), c-Src (Cell Signaling, #2110). Antibody to Lin28 (Proteintech group) was used for immunohistochemistry.
Cloning and plasmid construction. We subcloned mammalian Lin28 and LIN28B cDNA into pBabe.Puro and pMSCV.Neo retroviral vectors. pMSCV.Neo.let-7g construct was previously described 3 . We purchased LIN28B shRNA in lentiviral plasmid (TRCN0000122599) and control shRNA (SHC002V).
Immunohistochemistry. Sections of tissues were deparaffinized with xylene and rehydrated with graded series of ethanol (absolute, 95%, 80% and 50%, respectively, and distilled water), followed by two washes of 5 min each in PBS-T. Antigen retrieval was conducted for 20 min in sodium citrate buffer (10 mM pH 6) at 90-100 1C followed by wash with PBST (1 Â 5 min). We then incubated tissue sections for 10 min in 3% (v/v) hydrogen peroxide in methanol to block endogenous peroxidase activity. Next, sections were washed for 5 min in PBS-T and blocked at room temperature for 1 h by using 2% normal goat serum, 2% BSA and 0.1% Triton X-100 in PBS. We then incubated tissue sections in humidified chamber for overnight incubation at 4 1C with primary antibody (1/200 in TBST). Sections were subsequently washed with PBS-T (3 Â 5 min) and incubated at room temperature for 1 h with secondary antibody (goat antibody to rabbit). After a wash with PBS-T (3 Â 5 min), sections were incubated with ready-to-use streptavidin peroxidase (Lab Vision) for 10 min at room temperature and then color was developed by using a DAB kit (Vector Laboratories). We counterstained sections with hematoxylin.
Viral production. For ecotropic viral production, we transfected retroviral plasmid DNA and pCL-Eco into 293T cells in a 1:1 mass ratio and harvested virus after 48 h. For VSV-G pseudotyped lentivirus, viral plasmid, lentiviral gag/pol and VSV-G were transfected in a mass ratio of 1:0.9:0.1, and virus was harvested after 72 h. We used 1 ml of unconcentrated viral supernatant to infect 50,000 cells. Infected cells were selected on antibiotic before subsequent analysis.
Bisulfite sequencing. Bisulfite sequencing was done as described 54 with the commercially available EZ DNA Methylation Kit (Zymo Research). We designed primers using MethPrimer to target a region 1 kb downstream of the LIN28B transcriptional start site. Primer sequences are listed in Supplementary Table 6 online.
Transformation and growth assays. Soft agar assays were conducted essentially as described previously 55 . We stained colonies with 0.005% crystal violet and counted them after 3-4 weeks of growth.
Quantitative RT-PCR. Quantitative RT-PCR was used for detection of mature miRNA species as described previously 8 . We conducted mRNA expression analysis by quantitative PCR using SYBR green dye, with relative changes calculated by the DDC t method, or using LIN28B Taqman probe on samples. Primer sequences are listed in Supplementary Table 6 .
Microarray data analysis. Log 2 -transformed expression data were normalized to the average expression signal for normal tissue (where available), or rownormalized for the GSE9843 and GSE9891 datasets. We took the cutoff for overexpression as a normalized expression value of 2 or greater unless stated otherwise. For microarray profiling of cancer cell lines, the samples run were from the Sanger cCell line collection (see URLs section below) using an HT-HG_U133A chip; miRNAs were profiled using our previously described
